Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review

References

• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–117.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778.
   PubMed Web of Science ®Google Scholar
• Nikishina I, Shapovalenko A. Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy. Pediatr Rheumatol Online J. 2008;6(Suppl 1):P50–P50.
   Google Scholar
• Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheumatism. 2013;65(10):2499–2512.
   PubMed Web of Science ®Google Scholar
• Mori M, Takei S, Imagawa T, et al. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Mod Rheumatol. 2005;15(6):397–404.
   PubMedGoogle Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. pediatric rheumatology. group cs. N Engl J Med. 2000;342(11):763–769.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheumatism. 2008;58(5):1496–1504.
   PubMed Web of Science ®Google Scholar
• Brunner H, Ruperto N, Tzaribachev N, et al. A148: A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheumatol. 2014;66(S3):S191–S192.
   Web of Science ®Google Scholar
• Listing M, Monkemoller K, Liedmann I, et al. The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON). Arthritis Res Ther. 2018;20(1): 106. .
   PubMed Web of Science ®Google Scholar
• Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheumatism. 1997;40(7):1202–1209.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheumatism. 2003;48(1):218–226.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheumatism. 2006;54(6):1987–1994.
   PubMed Web of Science ®Google Scholar
• Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48(8):916–919.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheumatism. 2012;64(6):2012–2021.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41(12):2459–2465.
   PubMed Web of Science ®Google Scholar
• Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114–1122.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Vojinovic J, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816–824.
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67(8):2240–2249.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Takei S, Umebayashi H, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31(12):1713–1721.
   PubMed Web of Science ®Google Scholar
• Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–1441.
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Tse SML, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67(11):1503–1512.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–873. quiz 1165–6.
   PubMed Web of Science ®Google Scholar
• Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62(3):245–247.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheumatism. 2007;56(9):3096–3106.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–722.
   PubMed Web of Science ®Google Scholar
• Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605–1612.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21–29.
   PubMed Web of Science ®Google Scholar
• Keystone E, van der Heijde D, Mason D JR, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatism. 2008;58(11):3319–3329.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheumatism. 2010;62(6):1792–1802.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759–2770.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Tzaribachev N, Vega-Cornejo G, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol. 2018;70(7):1144–1154.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22(1):109–115.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–1117.
   PubMed Web of Science ®Google Scholar
• Opoka-Winiarska V, Zuber Z, Alexeeva E, et al. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. Clin Rheumatol. 2018;37(7):1807–1816.
   PubMed Web of Science ®Google Scholar
• Benedetti F, HI DB, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395.
   PubMed Web of Science ®Google Scholar
• Horneff G 1, Ganser G 2, Foeldvari I 3, et al. Pharmacovigilance of biologics for non-systemic juvenile idiopathic arthritis by the German biologics registry. [Results from the German Biologics JIA Registry (BIKER)]. 1Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, 2Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, 3Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, 4Prof.-Hess-Kinderklinik, Bremen, Berlin, Germany, 5Charité–Universitätsmedizin Berlin, Berlin, Germany, 6Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany; 2018.
   Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–265.
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheumatism. 2009;60(7):1884–1894.
   PubMed Web of Science ®Google Scholar
• Bigbee CL, Gonchoroff DG, Vratsanos G, et al. Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice. Arthritis Rheumatism. 2007;56(8):2557–2565.
   PubMed Web of Science ®Google Scholar
• Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011 Mar;50(3):552–562.
   Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.e2.
   PubMed Web of Science ®Google Scholar
• Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749–1755.
   PubMed Web of Science ®Google Scholar
• Puszczewicz MJ, Tuchocka-Piotrowska A, Majewski D, et al. Coincidence of juvenile idiopathic arthritis and multiple sclerosis: case report. Ann Acad Med Stetin. 2006;52(Suppl 2):85–88.
   PubMedGoogle Scholar
• Kaouther BA, Leila S, Salwa B, et al. Concurrence of juvenile idiopathic arthritis and multiple sclerosis. Case Rep Rheumatol. 2011;2011:162857.
   PubMedGoogle Scholar
• Toussirot E, Pertuiset E, Martin A, et al. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol. 2006;33(5):1027–1028.
   PubMed Web of Science ®Google Scholar
• Flemming GMC, Toth G, Gebauer C, et al. Crohn’s disease in a patient with juvenile idiopathic arthritis after starting etanercept therapy – causal link or only temporal coincidence? Klin Padiatr. 2013;225(6):350–351.
   PubMed Web of Science ®Google Scholar
• Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, et al. Emergence of Crohn’s disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence? J Gastrointestin Liver Dis. 2010;19(3):342.
   PubMed Web of Science ®Google Scholar
• Wiegering V, Morbach H, Dick A, et al. Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010;30(6):801–804.
   PubMed Web of Science ®Google Scholar
• Barthel D, Ganser G, Kuester R-M, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42(11):2160–2165.
   PubMed Web of Science ®Google Scholar
• Brewerton DA. Crohn’s disease and arthritis. J R Soc Med. 1981;74(7):478–479.
   PubMed Web of Science ®Google Scholar
• Schenck S, Rosenbauer J, Niewerth M, et al. Comorbidity of type 1 diabetes mellitus in patients with juvenile idiopathic arthritis. J Pediatr. 2018;192:196–203.
   PubMed Web of Science ®Google Scholar
• Kaatsch P. Pädiatrische hämatologie und onkologie: epidemiologie von krebserkrankungen im kindesalter. Berlin, Heidelberg: Springer; 2018.
   Google Scholar
• Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009;68(12):1819–1826.
   PubMed Web of Science ®Google Scholar
• Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics. 2015;9:1–6.
   PubMedGoogle Scholar
• Tarkiainen M, Tynjala P, Vahasalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2015;54(7):1170–1176.
   PubMed Web of Science ®Google Scholar
• Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheumatism. 2009;60(9):2794–2804.
   PubMed Web of Science ®Google Scholar
• Davies R, Southwood TR, Kearsley-Fleet L, et al. British society for paediatric and adolescent rheumatology etanercept cohort study. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015;67(9):2487–2494.
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51(8):1407–1415.
   PubMed Web of Science ®Google Scholar
• Horneff G, Seyger MMB, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn’s disease. J Pediatr. 2018;201:166–175.e3. DOI:10.1016/j.jpeds.2018.05.042
   PubMed Web of Science ®Google Scholar